Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ownership Breakdown Seagen Inc. SGEN

Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.


Top institutional share ownership of Seattle Genetics, Inc.

Name Shares Shares % change Value Value % change
Baker Bros. Advisors Lp 46,912,266 0.0% $6,757,712 -6.8%
Capital International Investors 15,465,358 34.4% $2,227,185 25.1%
Vanguard Group Inc 12,493,151 1.7% $2,210,539 25.0%
Wellington Management Group Llp 12,476,025 7.2% $1,797,170 -0.1%
BlackRock Inc. 11,432,260 -16.6% $2,022,825 2.5%
Price T Rowe Associates Inc /md/ 4,850,955 -26.9% $698,780 -31.9%
AGTHX - GROWTH FUND OF AMERICA Class A 4,770,825 0.0% $647,306 5.3%
Primecap Management Co/ca/ 4,588,610 -0.7% $811,909 21.9%
VGHCX - Vanguard Health Care Fund Investor Shares 4,431,828 8.4% $580,614 5.5%
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares 3,973,943 2.0% $572,446 -5.0%

Top institutional buyers of Seattle Genetics, Inc.

Name Shares % change Value % change Shares Value
ANCFX - AMERICAN FUNDS FUNDAMENTAL INVESTORS Class A 121.6% 106.5% 1,629,383 $234,713
ANWPX - NEW PERSPECTIVE FUND Class A 54.2% 43.7% 3,770,131 $543,087
Capital International Investors 34.4% 25.1% 15,465,358 $2,227,185
Jpmorgan Chase & Co 29.0% 58.4% 3,051,980 $540,018
Fmr Llc 17.9% 44.8% 2,671,697 $472,730
VGHCX - Vanguard Health Care Fund Investor Shares 8.4% 5.5% 4,431,828 $580,614
Wellington Management Group Llp 7.2% -0.1% 12,476,025 $1,797,170
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares 2.0% -5.0% 3,973,943 $572,446
Vanguard Group Inc 1.7% 25.0% 12,493,151 $2,210,539
Invesco Qqq Trust, Series 1 1.5% -5.4% 2,658,953 $383,022

Top institutional sellers of Seattle Genetics, Inc.

Name Shares % change Value % change Shares Value
Price T Rowe Associates Inc /md/ -26.9% -31.9% 4,850,955 $698,780
BlackRock Inc. -16.6% 2.5% 11,432,260 $2,022,825
Franklin Resources Inc -8.3% 12.6% 1,458,952 $258,146
Primecap Management Co/ca/ -0.7% 21.9% 4,588,610 $811,909
VHCOX - Vanguard Capital Opportunity Fund Investor Shares -0.6% -7.4% 1,831,092 $263,769
POAGX - PRIMECAP Odyssey Aggressive Growth Fund -0.6% -3.2% 1,650,593 $216,244

Information provided by Fintel.io